Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
2026. nov. 11.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
2026. nov. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Cicatricial Ectropion in the Setting of IL-13 Inhibition.
2026. okt. 1.· Journal of drugs in dermatology : JDD· PUBMED
Publikáció
Evidence that IL-4/IL-13-Responsive IGFLs Promote Allergic Skin Inflammation.
2026. szept. 30.· The Journal of investigative dermatology· PUBMED
Publikáció
IL-13 and skin fibrosis in inflammatory skin diseases.
2026. szept. 24.· Frontiers in immunology· PUBMED
Publikáció
Case Report: Differential response to IL-13 inhibition: lebrikizumab following primary tralokinumab failure in atopic dermatitis.
2026. szept. 23.· Frontiers in medicine· PUBMED
Publikáció
CCL5, CLEC11A, IL-7, IL-8, and IL-13: Diagnostic Serum Biomarkers of Gastric Cancer Identified in a 48-Multiplex Panel.
2026. szept. 9.· Oncology· PUBMED
Publikáció
Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.
2026. szept. 1.· Inflammatory bowel diseases· PUBMED
Publikáció
Persistent Patch Test Reactivity to Compositae Mix and Sesquiterpene Lactone Mix During Anti-IL-4/IL-13 Therapy in Two Cases.
2026. aug. 28.· Contact dermatitis· PUBMED
Publikáció
Case Report: Effective IL-4/IL-13 axis suppression and resolution of severe atopic dermatitis by dupilumab monotherapy in a patient with IPEX syndrome.
2026. aug. 17.· Frontiers in immunology· PUBMED
Publikáció
Nasal Lavage IL-4 and IL-13 in Cystic Fibrosis-Related Chronic Rhinosinusitis: Associations With Disease Severity and Potential Implications for Targeted Therapies.
2026. aug. 13.· International forum of allergy & rhinology· PUBMED
Publikáció
Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.
2026. júl. 28.· Diagnostics (Basel, Switzerland)· PUBMED
Publikáció
Comment on 'Should Paradoxical Psoriasis Trigger Rheumatological Surveillance During IL-4/IL-13 Blockade?'.
2026. júl. 24.· Clinical and experimental dermatology· PUBMED
Publikáció
IL-13 signaling in cDC2 is required for systemic anaphylactic responses.
2026. júl. 9.· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publikáció
Elevated IL-4 and IL-13 Expression in Hailey-Hailey Disease: Evidence for Th2-Mediated Pathogenesis and Targeted Treatment.
2026. júl. 6.· Journal of cutaneous pathology· PUBMED
Publikáció
Indole-3-carbinol attenuates DNCB-induced atopic dermatitis in mice by reducing inflammation and IL-4/IL-13 expression.
2026. júl. 2.· Biomolecules & biomedicine· PUBMED
Publikáció
Comment on: Bronchodilator response is linked with uncontrolled moderate-to-severe childhood asthma and elevated IL-4 and IL-13.
2026. júl. 1.· Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology· PUBMED
Publikáció
IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.
2026. jún. 22.· Cells· PUBMED
Publikáció
CagA-dependent expression of anti-inflammatory cytokine IL-13 and TNFRSF member Fn14 in Helicobacter pylori infected gastric cells and tissues.
2026. jún. 16.· Frontiers in microbiology· PUBMED
Publikáció
The airway epithelial muco-inflammatory response to IL-13 is exacerbated in cystic fibrosis.
2026. jún. 1.· American journal of respiratory cell and molecular biology· PUBMED
Publikáció
Bronchodilator response is linked with uncontrolled moderate-to-severe childhood asthma and elevated IL-4 and IL-13.
2026. jún. 1.· Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology· PUBMED
Publikáció
Dupilumab attenuate IL-4 and IL-13 synergistic effect on airway remodeling in asthma via blocking IL-4Rα/STAT6 axis.
2026. máj. 30.· Scientific reports· PUBMED
Publikáció
First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.
2026. máj. 28.· Frontiers in immunology· PUBMED
Publikáció
Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review.
2026. máj. 16.· Current allergy and asthma reports· PUBMED
Publikáció
Drug-induced sarcoidosis-like reaction following IL-4/IL-13 receptor blockade by dupilumab.
2026. máj. 13.· European journal of pediatrics· PUBMED
Publikáció
Association Between IL-4 (rs2243250) and IL-13 (rs20541) Gene Polymorphisms and Total IgE Levels in Bronchial Asthma: A Study from Aswan Governorate, Egypt.
2026. máj. 10.· Iranian journal of pathology· PUBMED
Publikáció
S100P mediates IL-13/ATF4-driven epithelial barrier dysfunction in eosinophilic asthma: a potential biomarker and therapeutic target.
2026. ápr. 24.· Journal of translational medicine· PUBMED
Publikáció
Vascular Immune Crosstalk in COVID-19: RAAS Biomarker Signature Linking Angiotensin II to Respiratory Compromise and Soluble ACE2 to IL-13 and FGF, Revealing Therapeutic Targets.
2026. ápr. 17.· International journal of molecular sciences· PUBMED
Publikáció
CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation.
2026. ápr. 10.· Journal of translational medicine· PUBMED
Publikáció
Design of binder proteins specific to IL-13.
2026. ápr. 2.· International journal of biological macromolecules· PUBMED